NCT05651841 (REVERT) is a Phase 3 clinical trial of Tezepelumab in Airway Remodelling, Asthmatic, sponsored by University Hospital, Montpellier.

Who is sponsoring NCT05651841?

NCT05651841 is sponsored by University Hospital, Montpellier.

What drugs are being tested in NCT05651841?

Interventions in NCT05651841: Tezepelumab, placebo.

What condition does NCT05651841 study?

NCT05651841 studies Airway Remodelling, Asthmatic.

Is NCT05651841 still recruiting?

NCT05651841 is currently recruiting now. Last updated 28 February 2024.

Last reviewed 2024-02-28 · How we verify

NCT05651841: REVERT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

REVErsing Airway Remodelling With Tezepelumab

Recruiting now Phase 3 Last updated 28 February 2024

What this trial tests

Phase 3 trial testing Tezepelumab in Airway Remodelling, Asthmatic in 90 participants. Currently enrolling.

Timeline

27 March 2023

Primary endpoint
1 December 2025

1 June 2026

Quick facts

Lead sponsor	University Hospital, Montpellier
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	90
Start date	27 March 2023
Primary completion	1 December 2025
Estimated completion	1 June 2026
Sites	12 locations across France

Drugs / interventions tested

Tezepelumab (TEZEPELUMAB) — full drug profile →
placebo

Conditions studied

Airway Remodelling, Asthmatic — all drugs for Airway Remodelling, Asthmatic →

Sponsor

University Hospital, Montpellier

Who can join

Adults 18 to 85, any sex, with Airway Remodelling, Asthmatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this protocol is to perform a first randomized controlled trial evaluating how Tezepelumab affects the bronchial morphology (and computed tomographic variables in general) of asthmatic patients. In parallel, the investigators also hope to reproduce clinical benefits and perform a transcriptomic study that will juxtapose changes in genetic expression with changes in bronchial morphology and inflammatory signatures. The general hypothesis is that tezepelumab treatment is capable of at least partially reversing bronchial remodelling as detected on computed-tomographic (CT) scans. The investigators also expect such reversal to occur within a unique physiological repair environment that will be reflected by transcriptomic profiles

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Biologics and airway remodeling in asthma: early, late, and potential preventive effects.
Varricchi G, Poto R, Lommatzsch M, Brusselle G, et al · · 2025 · cited 33× · PMID 39520155 · DOI 10.1111/all.16382
Targeting inflammation or remodeling in asthma? Is there a right way?
Domvri K, Porpodis K. · · 2023 · cited 2× · PMID 38076243 · DOI 10.3389/fmed.2023.1241920

Verify or expand the search:

Other trials of Tezepelumab

Trials testing the same drug.

NCT07520162 — A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab · Phase 3 · not yet recruiting
NCT07015996 — Efficacy of Tezepelumab in Peanut Oral Immunotherapy · Phase 2 · not yet recruiting
NCT07363642 — Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab · Phase 3 · recruiting
NCT07046117 — Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis · NA · not yet recruiting
NCT06951867 — Tezspire Cardiac Events PASS · recruiting

Other University Hospital, Montpellier trials

Trials by the same sponsor.

NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05651841 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
Last refreshed: 28 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05651841.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing